^
    Back
    Association details:
    Biomarker:MET amplification + MET overexpression
    Cancer:Non Small Cell Lung Cancer
    Drug:Tabrecta (capmatinib) (c-MET inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C4 – Case Studies
    New
    Source:
    Transl Lung Cancer Res
    Title:

    MYC amplification-conferred primary resistance to capmatinib in a MET-amplified NSCLC patient: a case report

    Excerpt:
    Capmatinib was administered as first-line treatment in an 82-year-old MET-amplified [gene copy number (GCN) 13.5] and MET overexpressed (immunohistochemical staining 3+/3, >50%) NSCLC patient. However, the tumor rapidly progressed and showed primary resistance to capmatinib.
    DOI:
    10.21037/tlcr-22-176